PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
34 hedge funds and large institutions have $478K invested in PLx Pharma Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 7 closing their positions.
17% less funds holding
Funds holding: 41 → 34 (-7)
43% less capital invested
Capital invested by funds: $833K → $478K (-$356K)
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SF
Synovus Financial
Columbus,
Georgia
|
+$7.06K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$2.64K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$437 |
| 4 |
BlackRock
New York
|
+$304 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
-$162K |
| 2 |
HF
HRT Financial
New York
|
-$14K |
| 3 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$12.7K |
| 4 |
Jane Street
New York
|
-$11.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.1K |
PLXP Hedge Fund Activity: Q1 2023 in Review
34 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q1 2023, worth a combined $478K — down 43% from $833K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PLXP and 0 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 4 added.
The largest buyer was Synovus Financial, adding an estimated $7.06K. The largest seller was Steel Grove Capital Advisors, exiting entirely with an estimated $162K sold.
- 34 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q1 2023, down from 41 in Q4 2022.
- Funds reported $478K of PLx Pharma Inc. Common Stock stock for Q1 2023, down 43% quarter-over-quarter.
- 0 funds opened new PLx Pharma Inc. Common Stock positions in Q1 2023 and 7 closed out, a net change of -7 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q1 2023 was Synovus Financial, an estimated $7.06K added.
- The largest PLx Pharma Inc. Common Stock seller in Q1 2023 was Steel Grove Capital Advisors, an estimated $162K sold.
Based on aggregated 13F filings for Q1 2023.